Kahn E M, Schulz S C, Perel J M, Alexander J E
Northeast Psychiatric Associates, Nashua, New Hampshire.
J Clin Psychopharmacol. 1990 Feb;10(1):54-7. doi: 10.1097/00004714-199002000-00011.
Serum haloperidol levels were measured in patients who received haloperidol alone and, subsequently, haloperidol in combination with carbamazepine or lithium carbonate. Haloperidol levels and the level- dose ratios dropped about 50% in patients receiving carbamazepine. They remained the same in most patients receiving lithium carbonate. One patient receiving added carbamazepine experienced worsening of symptoms; this was associated with a drop in serum haloperidol level. Two other patients receiving added carbamazepine showed significant symptom reduction, although they also sustained drops in serum haloperidol levels. It is not clear whether these two individuals benefited from a primary antipsychotic effect of carbamazepine or from reduction of "toxic" haloperidol levels. Serum levels of antipsychotic medication should be monitored carefully when these medications are prescribed in combination with carbamazepine.
对单独使用氟哌啶醇以及随后联合使用卡马西平或碳酸锂的患者进行了血清氟哌啶醇水平测定。接受卡马西平治疗的患者，其氟哌啶醇水平及血药浓度与剂量之比下降了约50%。接受碳酸锂治疗的大多数患者中，这些指标保持不变。一名加用卡马西平的患者症状恶化，这与血清氟哌啶醇水平下降有关。另外两名加用卡马西平的患者症状显著减轻，尽管他们的血清氟哌啶醇水平也持续下降。尚不清楚这两名患者是受益于卡马西平的主要抗精神病作用还是“毒性”氟哌啶醇水平的降低。当这些药物与卡马西平联合使用时，应仔细监测抗精神病药物的血清水平。
